When was Vicebio founded?

Vicebio was founded in 2019 and raised its 1st funding round 5 years after it was founded.

Where is Vicebio located?

Vicebio is headquartered in New York, United States. It is registered at SHOREDITCH HIGH STREET 168 box E1 6RA - LONDRE 2éme étage.

Is Vicebio a funded company?

Vicebio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Sep 23, 2024.

How much is Vicebio worth?

The last known valuation of Vicebio was $***** as of Jul 22, 2025.

When was the latest funding round of Vicebio?

Vicebio's latest funding was a $***** Series B round on Sep 23, 2024, with participation from 5 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $4.08B in funding in 2026 to date.

Where does Vicebio rank among its competitors?

Vicebio ranks 27th amongst 388 active competitors, of which 107 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Leyden Labs, which secured $45.5M in Jun, 2026.

Who are the top competitors of Vicebio?

Vicebio's top competitors include HOOKIPA Pharma, Atea and ImmunityBio. Among them, Leyden Labs secured the most recent funding round in June, 2026.

Vicebio - 2026 Company Profile, Team, Funding & Competitors

Q: Is Vicebio an acquired company?

Vicebio got acquired by Sanofi on Jul 22, 2025.

Vicebio is an acquired company based in New York (United States), founded in 2019. It operates as a Developer of vaccines to treat viral infectious diseases. Vicebio has raised $100M in funding from TCG Crossover, with last known valuation of $*****. The company has 388 active competitors, including 107 funded and 95 that have exited. Its top competitors include companies like HOOKIPA Pharma, Atea and ImmunityBio.

Company Details

Developer of vaccines to treat viral infectious diseases. The company has Molecular Clamp technology for high yield production of viral fusion proteins in native trimeric “prefusion” form. The lead candidate of the company includes VXB-211 which targets respiratory syncytial virus (RSV). The company has developed a pipeline for Metapneumovirus, influenza, and SARS-CoV-2.

Website: vicebio.com
Registered Address: SHOREDITCH HIGH STREET 168 box E1 6RA - LONDRE 2éme étage

Key Metrics

Founded Year

2019

Location

New York, United States

Stage

Acquired

Total Funding

$100M in 1 round

Latest Funding Round

Series B, Sep 23, 2024, $*****

Last Known Valuation

$***** as on Jul 22, 2025

Investors

TCG Crossover & 4 more

Ranked

27^th among 388 active competitors

Similar Companies

HOOKIPA Pharma & 486 more

Exit Details

Acquired by Sanofi (Jul 22, 2025)

View Vicebio's full profile

Vicebio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
VICEBIO LIMITED CIN: 0794.342.007 , Belgium, Active	Sep 14, 2018	-	-	-

Vicebio got acquired by Sanofi on Jul 22, 2025 at an acquisition amount of $*****.

Click here to take a look at Vicebio's acquisition in detail

Vicebio has raised a total funding of $100M over 1 round. Its latest funding round was a Series B round on Sep 23, 2024 for $*****. 5 investors participated in its latest round. Vicebio has 5 institutional investors.

Here is the list of recent funding rounds of Vicebio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 23, 2024	4198761	Series B	1152062	1552802	6305471	9201569

Access funding benchmarks and valuations. Sign up today!

View details of Vicebio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vicebio include HOOKIPA Pharma, Atea and ImmunityBio. Here is the list of Top 10 competitors of Vicebio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	70/100
2nd	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	Bain Capital Life Sciences, GSA Capital Partners ... & 18 others	67/100
3rd	ImmunityBio 2014, El Segundo (United States), Public	Developer of peptide-based vaccines for immunotherapy	$169M	Oberland Capital, NantWorks & 1 others	67/100
4th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
5th	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100
6th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
7th	Osivax 2017, Lyon (France), Series B	Developer of vaccines against constantly mutating pathogens	$42.2M	EIC Fund, Noshaq & 11 others	63/100
8th	Leyden Labs 2020, Leiden (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$303M	Google Ventures, Clavystbio & 14 others	63/100
9th	Ascletis Pharma 2011, Hangzhou (China), Public	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	62/100
10th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, America’s Seed Fund ... & 3 others	62/100
27th	Vicebio 2019, New York (United States), Acquired	Developer of vaccines to treat viral infectious diseases	$100M	Avoro Capital, VenBio & 3 others	55/100